Search

Your search keyword '"Carpentier C"' showing total 16 results
Start Over Author "Carpentier C" Publication Type Electronic Resources
16 results on '"Carpentier C"'

1. Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas

Author

Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., Idbaih, A., Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., and Idbaih, A.

Abstract

Item does not contain fulltext, BACKGROUND: Diffuse low-grade gliomas (LGGs) form a heterogeneous subgroup of gliomas in adults. Chromosome (chr) arms 1p/19q codeletion and IDH mutation have been shown to be closely associated with oligodendroglial phenotype and better prognosis. We sought to identify relevant biomarkers in non 1p/19q codeleted LGGs. METHODS: We characterized a retrospective series of 126 LGGs using genomic arrays, microsatellite analysis, IDH sequencing, MGMT promoter methylation assay, and p53 expression analysis. RESULTS: Our study confirms that 1p/19q codeletion, mutually exclusive with p53 overexpression, was associated with: (i) better prognosis, (ii) oligodendroglial phenotype, (iii) MGMT promoter methylation, and (iv) IDH mutation. Interestingly, 1p/19q codeleted tumors occur in older patients at diagnosis. Our study shows that non 1p/19q codeleted LGGs can be divided in 5 main genomic subgroups: (i) 11p loss, (ii) 19q loss (iii) 7 gain, (iv) 19 gain, and (v) unclassified. In non 1p/19q codeleted LGGs, we demonstrated that (i) 11p loss is associated with astrocytoma phenotype and has an independent negative prognostic value, and (ii) 19q loss diminished the favorable prognostic value of IDH mutation. Our findings were validated in an independent cohort of 98 LGGs. CONCLUSION: Novel genomic entities and biomarkers have been identified in non 1p/19q codeleted LGGs. Our findings may help to stratify non 1p/19q codeleted LGGs, facilitating future individualization of treatment. Further prospective studies are warranted to support our findings.

Published
2014

2. Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas

Author

Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., Idbaih, A., Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., and Idbaih, A.

Abstract

Item does not contain fulltext, BACKGROUND: Diffuse low-grade gliomas (LGGs) form a heterogeneous subgroup of gliomas in adults. Chromosome (chr) arms 1p/19q codeletion and IDH mutation have been shown to be closely associated with oligodendroglial phenotype and better prognosis. We sought to identify relevant biomarkers in non 1p/19q codeleted LGGs. METHODS: We characterized a retrospective series of 126 LGGs using genomic arrays, microsatellite analysis, IDH sequencing, MGMT promoter methylation assay, and p53 expression analysis. RESULTS: Our study confirms that 1p/19q codeletion, mutually exclusive with p53 overexpression, was associated with: (i) better prognosis, (ii) oligodendroglial phenotype, (iii) MGMT promoter methylation, and (iv) IDH mutation. Interestingly, 1p/19q codeleted tumors occur in older patients at diagnosis. Our study shows that non 1p/19q codeleted LGGs can be divided in 5 main genomic subgroups: (i) 11p loss, (ii) 19q loss (iii) 7 gain, (iv) 19 gain, and (v) unclassified. In non 1p/19q codeleted LGGs, we demonstrated that (i) 11p loss is associated with astrocytoma phenotype and has an independent negative prognostic value, and (ii) 19q loss diminished the favorable prognostic value of IDH mutation. Our findings were validated in an independent cohort of 98 LGGs. CONCLUSION: Novel genomic entities and biomarkers have been identified in non 1p/19q codeleted LGGs. Our findings may help to stratify non 1p/19q codeleted LGGs, facilitating future individualization of treatment. Further prospective studies are warranted to support our findings.

Published
2014

3. Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas

Author

Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., Idbaih, A., Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., and Idbaih, A.

Abstract

Item does not contain fulltext, BACKGROUND: Diffuse low-grade gliomas (LGGs) form a heterogeneous subgroup of gliomas in adults. Chromosome (chr) arms 1p/19q codeletion and IDH mutation have been shown to be closely associated with oligodendroglial phenotype and better prognosis. We sought to identify relevant biomarkers in non 1p/19q codeleted LGGs. METHODS: We characterized a retrospective series of 126 LGGs using genomic arrays, microsatellite analysis, IDH sequencing, MGMT promoter methylation assay, and p53 expression analysis. RESULTS: Our study confirms that 1p/19q codeletion, mutually exclusive with p53 overexpression, was associated with: (i) better prognosis, (ii) oligodendroglial phenotype, (iii) MGMT promoter methylation, and (iv) IDH mutation. Interestingly, 1p/19q codeleted tumors occur in older patients at diagnosis. Our study shows that non 1p/19q codeleted LGGs can be divided in 5 main genomic subgroups: (i) 11p loss, (ii) 19q loss (iii) 7 gain, (iv) 19 gain, and (v) unclassified. In non 1p/19q codeleted LGGs, we demonstrated that (i) 11p loss is associated with astrocytoma phenotype and has an independent negative prognostic value, and (ii) 19q loss diminished the favorable prognostic value of IDH mutation. Our findings were validated in an independent cohort of 98 LGGs. CONCLUSION: Novel genomic entities and biomarkers have been identified in non 1p/19q codeleted LGGs. Our findings may help to stratify non 1p/19q codeleted LGGs, facilitating future individualization of treatment. Further prospective studies are warranted to support our findings.

Published
2014

4. Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas

Author

Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., Idbaih, A., Alentorn, A., Thuijl, H.F. van, Marie, Y., Alshehhi, H., Carpentier, C., Boisselier, B., Laigle-Donadey, F., Mokhtari, K., Scheinin, I., Wesseling, P., Ylstra, B., Capelle, L., Hoang-Xuan, K., Sanson, M., Delattre, J.Y., Reijneveld, J.C., and Idbaih, A.

Abstract

Item does not contain fulltext, BACKGROUND: Diffuse low-grade gliomas (LGGs) form a heterogeneous subgroup of gliomas in adults. Chromosome (chr) arms 1p/19q codeletion and IDH mutation have been shown to be closely associated with oligodendroglial phenotype and better prognosis. We sought to identify relevant biomarkers in non 1p/19q codeleted LGGs. METHODS: We characterized a retrospective series of 126 LGGs using genomic arrays, microsatellite analysis, IDH sequencing, MGMT promoter methylation assay, and p53 expression analysis. RESULTS: Our study confirms that 1p/19q codeletion, mutually exclusive with p53 overexpression, was associated with: (i) better prognosis, (ii) oligodendroglial phenotype, (iii) MGMT promoter methylation, and (iv) IDH mutation. Interestingly, 1p/19q codeleted tumors occur in older patients at diagnosis. Our study shows that non 1p/19q codeleted LGGs can be divided in 5 main genomic subgroups: (i) 11p loss, (ii) 19q loss (iii) 7 gain, (iv) 19 gain, and (v) unclassified. In non 1p/19q codeleted LGGs, we demonstrated that (i) 11p loss is associated with astrocytoma phenotype and has an independent negative prognostic value, and (ii) 19q loss diminished the favorable prognostic value of IDH mutation. Our findings were validated in an independent cohort of 98 LGGs. CONCLUSION: Novel genomic entities and biomarkers have been identified in non 1p/19q codeleted LGGs. Our findings may help to stratify non 1p/19q codeleted LGGs, facilitating future individualization of treatment. Further prospective studies are warranted to support our findings.

Published
2014

5. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.

Author

Idbaih, A., Dalmasso, C., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J., Broet, P., Delattre, O., Mokhtari, K., Sanson, M., Delattre, J.Y., Bent, M. van den, Hoang-Xuan, K., Idbaih, A., Dalmasso, C., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J., Broet, P., Delattre, O., Mokhtari, K., Sanson, M., Delattre, J.Y., Bent, M. van den, and Hoang-Xuan, K.

Abstract

1 juni 2011, Item does not contain fulltext, Despite similar morphological aspects, anaplastic oligodendroglial tumors (AOTs) form a heterogeneous clinical subgroup of gliomas. The chromosome arms 1p/19q codeletion has been shown to be a relevant biomarker in AOTs and to be perfectly exclusive from EGFR amplification in gliomas. To identify new genomic regions associated with prognosis, 60 AOTs from the EORTC trial 26951 were analyzed retrospectively using BAC-array-based comparative genomic hybridization. The data were processed using a binary tree method. Thirty-three BACs with prognostic value were identified distinguishing four genomic subgroups of AOTs with different prognosis (p < 0.0001). Type I tumors (25%) were characterized by: (1) an EGFR amplification, (2) a poor prognosis, (3) a higher rate of necrosis, and (4) an older age of patients. Type II tumors (21.7%) had: (1) loss of prognostic BACs located on 1p tightly associated with 19q deletion, (2) a longer survival, (3) an oligodendroglioma phenotype, and (4) a frontal location in brain. Type III AOTs (11.7%) exhibited: (1) a deletion of prognostic BACs located on 21q, and (2) a short survival. Finally, type IV tumors (41.7%) had different genomic patterns and prognosis than type I, II and III AOTs. Multivariate analysis showed that genomic type provides additional prognostic data to clinical, imaging and pathological features. Similar results were obtained in the cohort of 45 centrally reviewed-validated cases of AOTs. Whole genome analysis appears useful to screen the numerous genomic abnormalities observed in AOTs and to propose new biomarkers particularly in the non-1p/19q codeleted AOTs.

Published
2011

6. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951

Author

Idbaih, A. (Ahmed), Dalmasso, C. (Cyril), Kouwenhoven, M.C.M. (Mathilde), Jeuken, J. (Judith), Carpentier, C. (Catherine), Gorlia, T.S. (Thierry), Kros, J.M. (Johan), French, P.J. (Pim), Teepen, J.L.J.M., Broët, P. (Philippe), Delattre, O. (Olivier), Mokhtari, K. (Karima), Sanson, M. (Marc), Bent, M.J. (Martin) van den, Hoang-Xuan, K. (Khe), Idbaih, A. (Ahmed), Dalmasso, C. (Cyril), Kouwenhoven, M.C.M. (Mathilde), Jeuken, J. (Judith), Carpentier, C. (Catherine), Gorlia, T.S. (Thierry), Kros, J.M. (Johan), French, P.J. (Pim), Teepen, J.L.J.M., Broët, P. (Philippe), Delattre, O. (Olivier), Mokhtari, K. (Karima), Sanson, M. (Marc), Bent, M.J. (Martin) van den, and Hoang-Xuan, K. (Khe)

Abstract

Despite similar morphological aspects, anaplastic oligodendroglial tumors (AOTs) form a heterogeneous clinical subgroup of gliomas. The chromosome arms 1p/19q codeletion has been shown to be a relevant biomarker in AOTs and to be perfectly exclusive from EGFR amplification in gliomas. To identify new genomic regions associated with prognosis, 60 AOTs from the EORTC trial 26951 were analyzed retrospectively using BAC-array-based comparative genomic hybridization. The data were processed using a binary tree method. Thirty-three BACs with prognostic value were identified distinguishing four genomic subgroups of AOTs with different prognosis (p < 0.0001). Type I tumors (25%) were characterized by: (1) an EGFR amplification, (2) a poor prognosis, (3) a higher rate of necrosis, and (4) an older age of patients. Type II tumors (21.7%) had: (1) loss of prognostic BACs located on 1p tightly associated with 19q deletion, (2) a longer survival, (3) an oligodendroglioma phenotype, and (4) a frontal location in brain. Type III AOTs (11.7%) exhibited: (1) a deletion of prognostic BACs located on 21q, and (2) a short survival. Finally, type IV tumors (41.7%) had different genomic patterns and prognosis than type I, II and III AOTs. Multivariate analysis showed that genomic type provides additional prognostic data to clinical, imaging and pathological features. Similar results were obtained in the cohort of 45 centrally reviewed-validated cases of AOTs. Whole genome analysis appears useful to screen the numerous genomic abnormalities observed in AOTs and to propose new biomarkers particularly in the non-1p/19q codeleted AOTs.

Published
2011
Full Text
View/download PDF

7. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.

Author

Idbaih, A., Dalmasso, C., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J., Broet, P., Delattre, O., Mokhtari, K., Sanson, M., Delattre, J.Y., Bent, M. van den, Hoang-Xuan, K., Idbaih, A., Dalmasso, C., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J., Broet, P., Delattre, O., Mokhtari, K., Sanson, M., Delattre, J.Y., Bent, M. van den, and Hoang-Xuan, K.

Abstract

01 juni 2011, Item does not contain fulltext, Despite similar morphological aspects, anaplastic oligodendroglial tumors (AOTs) form a heterogeneous clinical subgroup of gliomas. The chromosome arms 1p/19q codeletion has been shown to be a relevant biomarker in AOTs and to be perfectly exclusive from EGFR amplification in gliomas. To identify new genomic regions associated with prognosis, 60 AOTs from the EORTC trial 26951 were analyzed retrospectively using BAC-array-based comparative genomic hybridization. The data were processed using a binary tree method. Thirty-three BACs with prognostic value were identified distinguishing four genomic subgroups of AOTs with different prognosis (p < 0.0001). Type I tumors (25%) were characterized by: (1) an EGFR amplification, (2) a poor prognosis, (3) a higher rate of necrosis, and (4) an older age of patients. Type II tumors (21.7%) had: (1) loss of prognostic BACs located on 1p tightly associated with 19q deletion, (2) a longer survival, (3) an oligodendroglioma phenotype, and (4) a frontal location in brain. Type III AOTs (11.7%) exhibited: (1) a deletion of prognostic BACs located on 21q, and (2) a short survival. Finally, type IV tumors (41.7%) had different genomic patterns and prognosis than type I, II and III AOTs. Multivariate analysis showed that genomic type provides additional prognostic data to clinical, imaging and pathological features. Similar results were obtained in the cohort of 45 centrally reviewed-validated cases of AOTs. Whole genome analysis appears useful to screen the numerous genomic abnormalities observed in AOTs and to propose new biomarkers particularly in the non-1p/19q codeleted AOTs.

Published
2011

8. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.

Author

Idbaih, A., Dalmasso, C., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J., Broet, P., Delattre, O., Mokhtari, K., Sanson, M., Delattre, J.Y., Bent, M. van den, Hoang-Xuan, K., Idbaih, A., Dalmasso, C., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J., Broet, P., Delattre, O., Mokhtari, K., Sanson, M., Delattre, J.Y., Bent, M. van den, and Hoang-Xuan, K.

Abstract

01 juni 2011, Item does not contain fulltext, Despite similar morphological aspects, anaplastic oligodendroglial tumors (AOTs) form a heterogeneous clinical subgroup of gliomas. The chromosome arms 1p/19q codeletion has been shown to be a relevant biomarker in AOTs and to be perfectly exclusive from EGFR amplification in gliomas. To identify new genomic regions associated with prognosis, 60 AOTs from the EORTC trial 26951 were analyzed retrospectively using BAC-array-based comparative genomic hybridization. The data were processed using a binary tree method. Thirty-three BACs with prognostic value were identified distinguishing four genomic subgroups of AOTs with different prognosis (p < 0.0001). Type I tumors (25%) were characterized by: (1) an EGFR amplification, (2) a poor prognosis, (3) a higher rate of necrosis, and (4) an older age of patients. Type II tumors (21.7%) had: (1) loss of prognostic BACs located on 1p tightly associated with 19q deletion, (2) a longer survival, (3) an oligodendroglioma phenotype, and (4) a frontal location in brain. Type III AOTs (11.7%) exhibited: (1) a deletion of prognostic BACs located on 21q, and (2) a short survival. Finally, type IV tumors (41.7%) had different genomic patterns and prognosis than type I, II and III AOTs. Multivariate analysis showed that genomic type provides additional prognostic data to clinical, imaging and pathological features. Similar results were obtained in the cohort of 45 centrally reviewed-validated cases of AOTs. Whole genome analysis appears useful to screen the numerous genomic abnormalities observed in AOTs and to propose new biomarkers particularly in the non-1p/19q codeleted AOTs.

Published
2011

9. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951

Author

Idbaih, A, Dalmasso, C, Kouwenhoven, Mathilde, Jeuken, J, Carpentier, C, Gorlia, T, Kros, J.M., French, Pim, Teepen, J, Broet, P, Delattre, O, Mokhtari, K, Sanson, M, Delattre, JY, van den Bent, Martin, Hoang-Xuan, K, Idbaih, A, Dalmasso, C, Kouwenhoven, Mathilde, Jeuken, J, Carpentier, C, Gorlia, T, Kros, J.M., French, Pim, Teepen, J, Broet, P, Delattre, O, Mokhtari, K, Sanson, M, Delattre, JY, van den Bent, Martin, and Hoang-Xuan, K

Abstract

Despite similar morphological aspects, anaplastic oligodendroglial tumors (AOTs) form a heterogeneous clinical subgroup of gliomas. The chromosome arms 1p/19q codeletion has been shown to be a relevant biomarker in AOTs and to be perfectly exclusive from EGFR amplification in gliomas. To identify new genomic regions associated with prognosis, 60 AOTs from the EORTC trial 26951 were analyzed retrospectively using BAC-array-based comparative genomic hybridization. The data were processed using a binary tree method. Thirty-three BACs with prognostic value were identified distinguishing four genomic subgroups of AOTs with different prognosis (p < 0.0001). Type I tumors (25%) were characterized by: (1) an EGFR amplification, (2) a poor prognosis, (3) a higher rate of necrosis, and (4) an older age of patients. Type II tumors (21.7%) had: (1) loss of prognostic BACs located on 1p tightly associated with 19q deletion, (2) a longer survival, (3) an oligodendroglioma phenotype, and (4) a frontal location in brain. Type III AOTs (11.7%) exhibited: (1) a deletion of prognostic BACs located on 21q, and (2) a short survival. Finally, type IV tumors (41.7%) had different genomic patterns and prognosis than type I, II and III AOTs. Multivariate analysis showed that genomic type provides additional prognostic data to clinical, imaging and pathological features. Similar results were obtained in the cohort of 45 centrally reviewed-validated cases of AOTs. Whole genome analysis appears useful to screen the numerous genomic abnormalities observed in AOTs and to propose new biomarkers particularly in the non-1p/19q codeleted AOTs.

Published
2011

10. Genetic risk profiles identify different molecular etiologies for glioma

Author

Simon, M, Hosking, FJ, Marie, Y, Gousias, K, Boisselier, B, Carpentier, C, Schramm, J, Mokhtari, K, Hoang-Xuan, KH, Idbaih, A, Delattre, JY, Lathrop, M, Robertson, LB, Houlston, RS, Sanson, M, Simon, M, Hosking, FJ, Marie, Y, Gousias, K, Boisselier, B, Carpentier, C, Schramm, J, Mokhtari, K, Hoang-Xuan, KH, Idbaih, A, Delattre, JY, Lathrop, M, Robertson, LB, Houlston, RS, and Sanson, M

Published
2010

11. Genetic risk profiles identify different molecular etiologies for glioma

Author

Simon, M, Hosking, FJ, Marie, Y, Gousias, K, Boisselier, B, Carpentier, C, Schramm, J, Mokhtari, K, Hoang-Xuan, KH, Idbaih, A, Delattre, JY, Lathrop, M, Robertson, LB, Houlston, RS, Sanson, M, Simon, M, Hosking, FJ, Marie, Y, Gousias, K, Boisselier, B, Carpentier, C, Schramm, J, Mokhtari, K, Hoang-Xuan, KH, Idbaih, A, Delattre, JY, Lathrop, M, Robertson, LB, Houlston, RS, and Sanson, M

Published
2010

12. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.

Author

Idbaih, A., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J.L., Delattre, O., Delattre, J.Y., Bent, M. van den, Hoang-Xuan, K., Idbaih, A., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J.L., Delattre, O., Delattre, J.Y., Bent, M. van den, and Hoang-Xuan, K.

Abstract

Contains fulltext : 69651.pdf (publisher's version ) (Closed access), The chromosome (chr) 1p deletion is a favorable biomarker in oligodendroglial tumors and is even more powerful a marker when combined with chr 19q loss. As a result, the 1p deletion is taken into account more and more in clinical trials and the management of patients. However, the laboratory technique implemented for detection of this biomarker has been a topic of debate. To illustrate the usefulness of evaluating multiple loci, we here report two anaplastic oligodendrogliomas that were investigated using fluorescent in situ hybridization (FISH) and bacterial artificial chromosome (BAC)-array-based comparative genomic hybridization (aCGH). Indeed, segmental analysis using FISH, limited to chr 1p36 was unable to discriminate between complete and partial deletions of chrs 1p. However, complete and partial deletions of 1p are reported to have distinct clinical outcomes. Our results illustrate that aCGH (or other multiple loci technologies) provide complementary information to single locus technologies such as FISH because multiple loci technologies can evaluate the extent of the chr 1p deletion.

Published
2008

13. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.

Author

Idbaih, A., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J.L., Delattre, O., Delattre, J.Y., Bent, M. van den, Hoang-Xuan, K., Idbaih, A., Kouwenhoven, M., Jeuken, J.W.M., Carpentier, C., Gorlia, T., Kros, J.M., French, P., Teepen, J.L., Delattre, O., Delattre, J.Y., Bent, M. van den, and Hoang-Xuan, K.

Abstract

Contains fulltext : 69651.pdf (publisher's version ) (Closed access), The chromosome (chr) 1p deletion is a favorable biomarker in oligodendroglial tumors and is even more powerful a marker when combined with chr 19q loss. As a result, the 1p deletion is taken into account more and more in clinical trials and the management of patients. However, the laboratory technique implemented for detection of this biomarker has been a topic of debate. To illustrate the usefulness of evaluating multiple loci, we here report two anaplastic oligodendrogliomas that were investigated using fluorescent in situ hybridization (FISH) and bacterial artificial chromosome (BAC)-array-based comparative genomic hybridization (aCGH). Indeed, segmental analysis using FISH, limited to chr 1p36 was unable to discriminate between complete and partial deletions of chrs 1p. However, complete and partial deletions of 1p are reported to have distinct clinical outcomes. Our results illustrate that aCGH (or other multiple loci technologies) provide complementary information to single locus technologies such as FISH because multiple loci technologies can evaluate the extent of the chr 1p deletion.

Published
2008

14. The ATLAS semiconductor tracker end-cap module

Author

Abdesselam, A., Adkin, P. J., Allport, P. P., Alonso, J., Andricek, L., Anghinolfi, F., Antonov, A. A., Apsimon, R. J., Atkinson, T., Batchelor, L. E., Bates, R. L., Beck, G., Becker, H., Bell, P., Bell, W., Benes, P., Bernabeu, J., Bethke, S., Bizzell, J. P., Blocki, J., Broklova, Z., Broz, J., Bohm, J., Booker, P., Bright, G., Brodbeck, T. J., Bruckman, P., Buttari, C. M., Butterworth, J. M., Campabadal, F., Campbell, D., Carpentier, C., Carroll, J. L., Carter, A. A., Carter, J. R., Casse, G. L., Cermak, P., Chamizo, M., Charlton, D. G., Cheplakov, A., Chesi, E., Chilingarov, A., Chouridou, S., Chren, D., Christinet, A., Chu, M. L., Cindro, V., Clocio, A., Civera, J. V., Clark, A., Colijn, A. P., Cooke, P. A., Costa, M. J., Costanzo, D., Dabrowski, W., Danielsen, K. M., Davies, V. R., Dawson, I., de Jong, P., Dervan, P., Doherty, F., Dolezal, Z., Donega, M., D'Onofrio, M., Dorholt, O., Drasal, Z., Dowell, J. D., Duerdoth, I. P., Duxfield, R., Dwuznik, M., Easton, J. M., Eckert, S., Eklund, L., Escobar, C., Fadeyev, V., Fasching, D., Feld, L., Ferguson, D. P. S., Ferrari, P., Ferrere, D., Fleta, C., Fortin, R., Foster, J. M., Fowler, C., Fox, H., Freestone, J., French, R. S., Fuster, J., Gadomski, S., Gallop, B. J., Garcia, C., Garcia-Navarro, J. E., Gibson, S., Gilchriese, M. G. D., Gonzalez, F., Gonzalez-Sevilla, S., Goodrick, M. J., Gorisek, A., Gornicki, E., Greenall, A., Greenfield, D., Gregory, S., Grigorieva, I. G., Grillo, A. A., Grosse-Knetter, J., Gryska, C., Guipet, A., Haber, C., Hara, K., Hartjes, F. G., Hauff, D., Haywood, S. J., Hegeman, S. J., Heinzinger, K., Hessey, N. P., Heusch, C., Hicheur, A., Hill, J. C., Hodgkinson, M., Hodgson, P., Horazdovsky, T., Hollins, T. I., Hou, L. S., Hou, S., Hughes, G., Huse, T., Ibbotson, M., Iglesias, M., Ikegami, Y., Ilyashenko, I., Issever, C., Jackson, J. N., Jakobs, K., Jared, R. C., Jarron, P., Johansson, P., Jones, R. W. L., Jones, T. J., Joos, D., Joseph, J., Jovanovic, P., Jusko, O., Jusko, V., Kaplon, J., Kazi, S., Ketterer, Ch., Kholodenko, A. G., King, B. T., Kodys, P., Koffeman, E., Kohout, Z., Kohriki, T., Kondo, T., Koperny, S., Koukol, H., Kral, V., Kramberger, G., Kubik, P., Kudlaty, J., Lacasta, C., Lagouri, T., Lee, S. C., Leney, K., Lenz, S., Lester, C. G., Liebicher, K., Limper, M., Lindsay, S., Linhart, V., Llosa, G., Loebinger, F. K., Lozano, M., Ludwig, I., Ludwig, J., Lutz, G., Lys, J., Maassen, M., Macina, D., Macpherson, A., MacWaters, C., Magrath, C. A., Malecki, P., Mandic, I., Mangin-Brinet, M., Marti-Garcia, S., Matheson, J. P., Matson, R. M., McMahon, S. J., McMahon, T. J., Meinhardt, J., Mellado, B., Melone, J. J., Mercer, I. J., Messmer, I., Mikulec, B., Mikuz, M., Minano, M., Mitsouak, V. A., Modesto, P., Moed, S., Mohn, B., Moncrieff, S., Moorhead, G., Morris, F. S., Morris, J., Morrissey, M., Moser, H. G., Moszczynski, A., Muijs, A. J. M., Murray, W. J., Muskett, D., Nacher, J., Nagai, K., Nakano, I., Nickerson, R. B., Nisius, R., Oye, O. K., O'Shea, V., Paganis, E., Parker, M. A., Parzefall, U., Pater, J. R., Peeters, S. J. M., Pellegrini, G., Pelleriti, G., Pernegger, H., Perrin, E., Phillips, P. W., Pilavova, L. V., Poltorak, K., Pospisil, S., Postranecky, M., Pritchard, T., Prokofiev, K., Rafi, J. M., Raine, C., Ratoff, P. N., Reznicek, P., Riadovikov, V. N., Richter, R. H., Robichaud-Veronneau, A., Robinson, D., Rodriguez-Oliete, R., Roe, S., Rudge, A., Runge, K., Saavedra, A., Sadrozinski, H. F. W., Sanchez, F. J., Sandaker, H., Saxon, D. H., Scheirich, D., Schieck, J., Seiden, A., Sfyrla, A., Slavicek, T., Smith, K. M., Smith, N. A., Snow, S. W., Solar, M., Sopko, B., Sopko, V., Sospedra, L., Spencer, E., Stanecka, E., Stapnes, S., Stastny, J., Strachko, V., Stradling, A., Stugu, B., Su, D. S., Sutcliffe, P., Szczygiel, R., Tanaka, R., Taylor, G., Teng, P. K., Terada, S., Thompson, R. J., Titov, M., Toczek, B., Tovey, D. R., Tratzl, G., Troitsky, V. L., Tseng, J., Turala, M., Turner, P. R., Tyndel, M., Ullan, M., Unno, Y., Vickey, T., Van der Kraaij, E., Viehhauser, G., Villani, E. G., Vitek, T., Anh, T. Vu, Vorobiev, A. P., Vossebeld, J. H., Wachler, M., Wallny, R., Ward, C. P., Warren, M. R. M., Webel, M., Weber, M., Weidberg, A. R., Weilhammer, P., Wells, P. S., Wetzel, P., Whitley, M., Wiesmann, M., Wilhelm, I., Willenbrock, M., Wilmut, I., Wilson, J. A., Winton, J., Wolter, M., Wormald, M. P., Wu, S. L., Wu, X., Zhu, H., Bingefors, Nils, Brenner, Richard, Ekelöf, Tord, Abdesselam, A., Adkin, P. J., Allport, P. P., Alonso, J., Andricek, L., Anghinolfi, F., Antonov, A. A., Apsimon, R. J., Atkinson, T., Batchelor, L. E., Bates, R. L., Beck, G., Becker, H., Bell, P., Bell, W., Benes, P., Bernabeu, J., Bethke, S., Bizzell, J. P., Blocki, J., Broklova, Z., Broz, J., Bohm, J., Booker, P., Bright, G., Brodbeck, T. J., Bruckman, P., Buttari, C. M., Butterworth, J. M., Campabadal, F., Campbell, D., Carpentier, C., Carroll, J. L., Carter, A. A., Carter, J. R., Casse, G. L., Cermak, P., Chamizo, M., Charlton, D. G., Cheplakov, A., Chesi, E., Chilingarov, A., Chouridou, S., Chren, D., Christinet, A., Chu, M. L., Cindro, V., Clocio, A., Civera, J. V., Clark, A., Colijn, A. P., Cooke, P. A., Costa, M. J., Costanzo, D., Dabrowski, W., Danielsen, K. M., Davies, V. R., Dawson, I., de Jong, P., Dervan, P., Doherty, F., Dolezal, Z., Donega, M., D'Onofrio, M., Dorholt, O., Drasal, Z., Dowell, J. D., Duerdoth, I. P., Duxfield, R., Dwuznik, M., Easton, J. M., Eckert, S., Eklund, L., Escobar, C., Fadeyev, V., Fasching, D., Feld, L., Ferguson, D. P. S., Ferrari, P., Ferrere, D., Fleta, C., Fortin, R., Foster, J. M., Fowler, C., Fox, H., Freestone, J., French, R. S., Fuster, J., Gadomski, S., Gallop, B. J., Garcia, C., Garcia-Navarro, J. E., Gibson, S., Gilchriese, M. G. D., Gonzalez, F., Gonzalez-Sevilla, S., Goodrick, M. J., Gorisek, A., Gornicki, E., Greenall, A., Greenfield, D., Gregory, S., Grigorieva, I. G., Grillo, A. A., Grosse-Knetter, J., Gryska, C., Guipet, A., Haber, C., Hara, K., Hartjes, F. G., Hauff, D., Haywood, S. J., Hegeman, S. J., Heinzinger, K., Hessey, N. P., Heusch, C., Hicheur, A., Hill, J. C., Hodgkinson, M., Hodgson, P., Horazdovsky, T., Hollins, T. I., Hou, L. S., Hou, S., Hughes, G., Huse, T., Ibbotson, M., Iglesias, M., Ikegami, Y., Ilyashenko, I., Issever, C., Jackson, J. N., Jakobs, K., Jared, R. C., Jarron, P., Johansson, P., Jones, R. W. L., Jones, T. J., Joos, D., Joseph, J., Jovanovic, P., Jusko, O., Jusko, V., Kaplon, J., Kazi, S., Ketterer, Ch., Kholodenko, A. G., King, B. T., Kodys, P., Koffeman, E., Kohout, Z., Kohriki, T., Kondo, T., Koperny, S., Koukol, H., Kral, V., Kramberger, G., Kubik, P., Kudlaty, J., Lacasta, C., Lagouri, T., Lee, S. C., Leney, K., Lenz, S., Lester, C. G., Liebicher, K., Limper, M., Lindsay, S., Linhart, V., Llosa, G., Loebinger, F. K., Lozano, M., Ludwig, I., Ludwig, J., Lutz, G., Lys, J., Maassen, M., Macina, D., Macpherson, A., MacWaters, C., Magrath, C. A., Malecki, P., Mandic, I., Mangin-Brinet, M., Marti-Garcia, S., Matheson, J. P., Matson, R. M., McMahon, S. J., McMahon, T. J., Meinhardt, J., Mellado, B., Melone, J. J., Mercer, I. J., Messmer, I., Mikulec, B., Mikuz, M., Minano, M., Mitsouak, V. A., Modesto, P., Moed, S., Mohn, B., Moncrieff, S., Moorhead, G., Morris, F. S., Morris, J., Morrissey, M., Moser, H. G., Moszczynski, A., Muijs, A. J. M., Murray, W. J., Muskett, D., Nacher, J., Nagai, K., Nakano, I., Nickerson, R. B., Nisius, R., Oye, O. K., O'Shea, V., Paganis, E., Parker, M. A., Parzefall, U., Pater, J. R., Peeters, S. J. M., Pellegrini, G., Pelleriti, G., Pernegger, H., Perrin, E., Phillips, P. W., Pilavova, L. V., Poltorak, K., Pospisil, S., Postranecky, M., Pritchard, T., Prokofiev, K., Rafi, J. M., Raine, C., Ratoff, P. N., Reznicek, P., Riadovikov, V. N., Richter, R. H., Robichaud-Veronneau, A., Robinson, D., Rodriguez-Oliete, R., Roe, S., Rudge, A., Runge, K., Saavedra, A., Sadrozinski, H. F. W., Sanchez, F. J., Sandaker, H., Saxon, D. H., Scheirich, D., Schieck, J., Seiden, A., Sfyrla, A., Slavicek, T., Smith, K. M., Smith, N. A., Snow, S. W., Solar, M., Sopko, B., Sopko, V., Sospedra, L., Spencer, E., Stanecka, E., Stapnes, S., Stastny, J., Strachko, V., Stradling, A., Stugu, B., Su, D. S., Sutcliffe, P., Szczygiel, R., Tanaka, R., Taylor, G., Teng, P. K., Terada, S., Thompson, R. J., Titov, M., Toczek, B., Tovey, D. R., Tratzl, G., Troitsky, V. L., Tseng, J., Turala, M., Turner, P. R., Tyndel, M., Ullan, M., Unno, Y., Vickey, T., Van der Kraaij, E., Viehhauser, G., Villani, E. G., Vitek, T., Anh, T. Vu, Vorobiev, A. P., Vossebeld, J. H., Wachler, M., Wallny, R., Ward, C. P., Warren, M. R. M., Webel, M., Weber, M., Weidberg, A. R., Weilhammer, P., Wells, P. S., Wetzel, P., Whitley, M., Wiesmann, M., Wilhelm, I., Willenbrock, M., Wilmut, I., Wilson, J. A., Winton, J., Wolter, M., Wormald, M. P., Wu, S. L., Wu, X., Zhu, H., Bingefors, Nils, Brenner, Richard, and Ekelöf, Tord

Abstract

The challenges for the tracking detector systems at the LHC are unprecedented in terms of the number of channels, the required read-out speed and the expected radiation levels. The ATLAS Semiconductor Tracker. (SCT) end-caps have a total of about 3 million electronics channels each reading out every 25 ns into its own on-chip 3.3 mu s buffer. The highest anticipated dose after 10 years operation is 1.4x10(14) cm(-2) in units of 1 MeV neutron equivalent (assuming the damage factors scale with the non-ionising energy loss). The forward tracker has 1976 double-sided modules, mostly of area similar to 70 cm(2), each having 2 x 768 strips read out by six ASICs per side. The requirement to achieve an average perpendicular radiation length of 1.5% X-0, while coping with up to 7 W dissipation per module (after irradiation), leads to stringent constraints on the thermal design. The additional requirement of 1500e(-) equivalent noise charge (ENC) rising to only 1800e(-) ENC after irradiation, provides stringent design constraints on both the high-density Cu/Polyimide flex read-out circuit and the ABCD3TA read-out ASICs. Finally, the accuracy of module assembly must not compromise the 16 mu m (r phi) resolution perpendicular to the strip directions or 580 mu m radial resolution coming from the 40 mrad front-back stereo angle. A total of 2210 modules were built to the tight tolerances and specifications required for the SCT. This was 234 more than the 1976 required and represents a yield of 93%. The component flow was at times tight, but the module production rate of 40-50 per week was maintained despite this. The distributed production was not found to be a major logistical problem and it allowed additional flexibility to take advantage of where the effort was available, including any spare capacity, for building the end-cap modules. The collaboration that produced the ATLAS SCT end-cap modules kept in close contact at all times so that the effects of shortages or stoppages at

Published
2007
Full Text
View/download PDF

15. Mosselen en algen als poortwachters [Thema: Waterproductiebedrijf Heel]

Author

Hoogh-Carpentier, C. de, Diepenbeek, P. van, Engels, P., Noij, T., Hoogh-Carpentier, C. de, Diepenbeek, P. van, Engels, P., and Noij, T.

Abstract

Op drinkwaterproductiebedrijf Heel wordt de kwaliteit van het ingenomen Maaswater bewaakt door een fysisch-chemisch meetprogramma in combinatie met een biologisch early warning system (BEWS). Het BEWS bestaat uit een mosselmonitor en een algentoximeter. Uitleg over de principes en werking van deze monitoren, de gehanteerde criteria voor de keuze van een BEWS (monitoringsstrategie), en de implementatie van beide systemen. Na het vaststellen van de basisinstellingen en condities waarbij de monitor routinematig moet kunnen functioneren is d.m.v. spike-testen de reactie van de monitor op voor het stroomgebied relevante verontreinigingen onderzocht ( vooral stoffen afkomstig van landbouw, verkeer, bedrijfsmatige activiteiten en industrieel afvalwater)

Published
2002

16. Microtox kan zinvolle aanvulling op monitoring zijn : seminar over het 'integraal meten' van de waterkwaliteit

Author

Denneman, W.D., Carpentier, C., Denneman, W.D., and Carpentier, C.

Abstract

Verslag van een symposium over integrale waterkwaliteitsmonitoring (chemisch, biologisch en toxicologisch) van oppervlakte-, afval- en drinkwater. Speciale aandacht voor het Microtox-OS Test System, waarmee via bioassay de toxiciteit van een waterstroom on-line wordt gemeten, en de HPLC-fingerprint/toxprint, een methode waarbij chemische en toxicologische technieken gelijktijdig worden toegepast

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results